Biogen Treads Tricky Path Between Politicians, Investors

Biogen is taking a political risk with aggressive multiple sclerosis drug pricing, but the company is under pressure to boost its share price.

from WSJ.com: Markets http://ift.tt/2vKgUK5
via https://ifttt.com/ IFTTT